JNJ - Johnson & Johnson sees positive data from pair of multiple myeloma approaches at ASH

At the American Society of Hematology annual meeting over the weekend, Johnson & Johnson (JNJ -0.5%) posted attention-getting data on a pair of approaches to multiple myeloma. One study confirmed the company's cilta-cel as the most efficacious CAR-T therapy, with more than three-quarters of patients treated with the experimental therapy alive at least a year without their cancer worsening. The results have been stronger than those of a rival CAR-T therapy from Bristol Myers Squibb (BMY -1.1%) and Bluebird Bio (BLUE -0.4%), who might now face some long-run pressure to come up with a better approach. Toxicity is still an issue for cilta-cel, with six subjects dying, leaving 97 evaluable subjects. But overall remission rate is at 97% (vs. 73% overall, or 82% at highest dose, for the BMY/Bluebird idle-cel). Meanwhile, in an indication that multiple myeloma approaches vary beyond targeting the BCMA antigen, JNJ's talquetamab impressed with data from

For further details see:

Johnson & Johnson sees positive data from pair of multiple myeloma approaches at ASH